Cardiovascular Disease in Adult Cancer Survivors: a Review of Current Evidence, Strategies for Prevention and Management, and Future Directions for Cardio-oncology

Muhandiramge, Jaidyn; Zalcberg, John; Londen, G J. Van; Warner, Erica T.; Carr, Prudence R.; Haydon, Andrew; Orchard, Suzanne G

doi:10.1007/s11912-022-01309-w

Cited by 15 publications

(12 citation statements)

References 107 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This finding seems to be in contrast with the contemporary tendency in the general US population, where the age-adjusted decline in cardiovascular disease mortality has slowed in recent years [18,27]. This discrepancy might be explained by the advancement in consensus statements on recommended definitions and practices in the field of cardio-oncology over the past 2 decades [28][29][30][31][32][33]. These advancements in the field have likely led to improved management and prevention of cardiovascular disease in patients with GC.…”

Section: Discussionmentioning

confidence: 96%

Causes of Death Following Gastric Cancer Diagnosis: A Population-Based Analysis

Lou¹,

Hu²,

Lü³

et al. 2023

Med Sci Monit

View full text Add to dashboard Cite

Conflict of interest: None declared Background:Causes of death (CODs) in patients with gastric cancer (GC) need to be studied. We examined the cancer-specific and non-cancer deaths among patients diagnosed with GC from 1975 to 2019. Material/Methods:We obtained medical records from the Surveillance, Epidemiology, and End Results (SEER) database. We used SEER*Stat software to calculate standardized mortality ratios (SMRs) for specific CODs and performed a competing risk analysis to evaluate the cumulative mortality of specific CODs. Results:The final study cohort included 42 813 patients with GC, with a mean age at diagnosis of 67.7 years. As the end of 2021, a total of 36 924 (86.2%) patients died. Of these deaths, 24 625 (66.7%) were from GC, 6513 (17.6%) were from other types of cancers, and 5786 (15.7%) were from non-cancer causes. The most prevalent noncancer CODs were heart diseases (2104; 5.7%), cerebrovascular diseases (501; 1.4%), and pneumonia/influenza (335; 0.9%). Among patients who survived over 5 years, non-cancer causes surpassed GC as the main CODs. Patients with GC had a higher risk of dying from many non-cancer causes than expected in the general population, particularly from suicide (SMR, 3.03; 95% CI, 2.35-3.85) and septicemia (SMR, 2.93; 95% CI, 2.51-3.4).The competing risk analysis showed that the cumulative mortality of GC gradually declined with a more recent diagnosis. Conclusions:Although GC was the leading COD among patients with GC, non-cancer CODs accounted for a substantial number of deaths. These findings provide useful guidance on potential death risks among patients with GC.

show abstract

Section: Discussionmentioning

confidence: 96%

Causes of Death Following Gastric Cancer Diagnosis: A Population-Based Analysis

Lou¹,

Hu²,

Lü³

et al. 2023

Med Sci Monit

View full text Add to dashboard Cite

show abstract

“…The main sources of cardiac toxicity are drug toxicity and high-energy radiation injury. [15,16] The main manifestations are cardiac systolic and diastolic function decline, myocardial ischemia, valvar heart disease and coronary artery injury diseases. [17][18][19] For example, vascular endothelial growth factor receptor tyrosine kinase inhibitors can induce hypertension, proteinuria and myocardial ischemia.…”

Section: Discussionmentioning

confidence: 99%

Recent death early warning value of ECG changes in patients with NSCLC

Liu,

Cai,

Wang

et al. 2023

Medicine

View full text Add to dashboard Cite

We aimed to explore the predictive value of abnormal electrocardiogram (ECG) changes in non-small-cell lung carcinoma non-small cell lung cancer (NSCLC) patients for near-term mortality. Seventy-eight NSCLC patients hospitalized in Chaohu Hospital Affiliated to Anhui Medical University from October 2017 to August 2021 were selected as the observation group. Baseline medical history and type of ECG abnormalities were the same. Seventy-eight patients were included in the control group. To compare the difference in mortality within 3 months between the observation group and the control group after the occurrence of the same type of electrocardiogram abnormalities, and to explore the value of electrocardiogram abnormalities in the early warning of NSCLC patients recent death. When the average ventricular rate of patients in the observation group was ≥100 beats/minute, ST-segment depression ≥0.05 mm, QRS voltage decrease ≥0.5 mm, new atrial fibrillation and other electrocardiogram changes, all patients died within 3 months. The control group with the same abnormal ECG had no death within 3 months (P < .05). In the resting 12-lead synchronous ECG in NSCLC patients, when the average ventricular rate ≥100 beats/minute, QRS wave voltage significantly decreased ≥0.5 mm, ST segment depression ≥0.05 mm, new atrial fibrillation appeared, it suggested that the patients’ cardiac function decreased and the potential for near-term adverse outcomes is high.

show abstract

“…It is important to recognize that although effective management and early intervention for CVD related to cancer treatment has been instituted into clinical practice in many oncology and cardio-oncology centers around the world the implementation of cardiovascular screening and management of disease risk is often not continued as routine practice in long-term survivors. 190 An optimistic outlook can be had that we will see a more complete understanding of the long-term cardiovascular consequences of prohypertensive cancer therapies given the pace of progress within the field of cardio-oncology itself. However, this will require several important changes such as Increasing the scope of CVD screening and the duration of follow-up of cardio-oncology patients beyond there discharge from active treatment.…”

Section: Long-term Outcomes Of Cancer Therapy-related Hypertensionmentioning

confidence: 99%

“…There is evolving interest in gaining insight into the true ramifications that cardiovascular diseases such as hypertension and in particular cancer treatment-related hypertension may have on both long-term patient morbidity and mortality. 190 The data for long-term outcomes of therapy-related hypertension is extremely limited and in general, long-term CVD for patients with cancer has often been extrapolated from childhood cancer survivor cohorts; however, these data may not be accurate given the exponential growth in available novel anticancer therapies over the past decade. Nevertheless, poorly controlled hypertension is a clear risk factor for development of heart failure during treatment with anthracyclines, ibrutinib, and VEGFi.…”

Section: Parp Inhibitorsmentioning

confidence: 99%

Section: Parp Inhibitorsmentioning

confidence: 99%

See 1 more Smart Citation

Established and Emerging Cancer Therapies and Cardiovascular System: Focus on Hypertension—Mechanisms and Mitigation

et al. 2023

View full text Add to dashboard Cite

Cardiovascular disease and cancer are 2 of the leading causes of death worldwide. Although improvements in outcomes have been noted for both disease entities, the success of cancer therapies has come at the cost of at times very impactful adverse events such as cardiovascular events. Hypertension has been noted as both, a side effect as well as a risk factor for the cardiotoxicity of cancer therapies. Some of these dynamics are in keeping with the role of hypertension as a cardiovascular risk factor not only for heart failure, but also for the development of coronary and cerebrovascular disease, and kidney disease and its association with a higher morbidity and mortality overall. Other aspects such as the molecular mechanisms underlying the amplification of acute and long-term cardiotoxicity risk of anthracyclines and increase in blood pressure with various cancer therapeutics remain to be elucidated. In this review, we cover the latest clinical data regarding the risk of hypertension across a spectrum of novel anticancer therapies as well as the underlying known or postulated pathophysiological mechanisms. Furthermore, we review the acute and long-term implications for the amplification of the development of cardiotoxicity with drugs not commonly associated with hypertension such as anthracyclines. An outline of management strategies, including pharmacological and lifestyle interventions as well as models of care aimed to facilitate early detection and more timely management of hypertension in patients with cancer and survivors concludes this review, which overall aims to improve both cardiovascular and cancer-specific outcomes.

show abstract

Cardiovascular Disease in Adult Cancer Survivors: a Review of Current Evidence, Strategies for Prevention and Management, and Future Directions for Cardio-oncology

Cited by 15 publications

References 107 publications

Causes of Death Following Gastric Cancer Diagnosis: A Population-Based Analysis

Causes of Death Following Gastric Cancer Diagnosis: A Population-Based Analysis

Recent death early warning value of ECG changes in patients with NSCLC

Established and Emerging Cancer Therapies and Cardiovascular System: Focus on Hypertension—Mechanisms and Mitigation

Contact Info

Product

Resources

About